ERBB2 and breast cancer: PIK3CA mutations have been reported to be associated with markers of good prognosis, such as high ER, high PgR, smaller size, earlier stage, lower grade [5-7,13,14] and better outcome in ER+/HER2- disease, as well as with good prognosis with tamoxifen monotherapy, relapse-free survival, overall survival and BC-specific survival [5,6,16].